CADTH | Evidence Driven
CADTH | Evidence Driven

Opdivo for Non-Small Cell Lung Cancer – Details

Détails

Fichiers
Generic Name:
Nivolumab
État du projet:
Terminé
Domaine thérapeutique:
Metastatic non small cell lung cancer
Fabricant:
Bristol-Myers Squibb Canada
Brand Name:
Opdivo
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0069-000
Statut de l’AC au moment du dépôt:
Pré AC
Strength:
40mg/4mL and 100mg/10mL vials
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer
Funding Request:
For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after chemotherapy
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Demandée et accordée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

Fichiers

Provincial Funding Summary Résumé, financement provincial Afficher le PDF
Nivolumab (Opdivo) Non-Small Cell Lung Cancer – pERC Final Recommendation Recommandation finale 03 juin 2016 Afficher le PDF
Nivolumab (Opdivo) Non-Small Cell Lung Cancer – Final Clinical Guidance Report Rapports d'orientation 03 juin 2016 Afficher le PDF
Nivolumab (Opdivo) Non-Small Cell Lung Cancer – Final Economic Guidance Report Rapports d'orientation 01 avril 2016 Afficher le PDF
Nivolumab (Opdivo) Non-Small Cell Lung Cancer – pERC Initial Recommendation Recommandation initiale 01 avril 2016 Afficher le PDF
Nivolumab (Opdivo) Non-Small Cell Lung Cancer – PAG Feedback on Initial Recommendation Rétroaction 03 juin 2016 Afficher le PDF
Nivolumab (Opdivo) Non-Small Cell Lung Cancer – Manufacturer Feedback on Initial Recommendation Rétroaction 03 juin 2016 Afficher le PDF
Nivolumab (Opdivo) Non-Small Cell Lung Cancer – Patient Advocacy Group COI Declarations Déclarations de conflit d’intérêts 03 juin 2016 Afficher le PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Dernière mise à jour : 02 septembre 2016